Human PAC1 antibodies
AssigneeAmgen Inc.
InventorsCen Xu, Agnes Eva Hamburger
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
Claims19
A method for inhibiting binding of pituitary adenylate cyclase activating polypeptide (PACAP) to a human pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) in a patient in need thereof comprising administering to the patient an isolated monoclonal antibody that specifically binds to human PAC1, wherein the monoclonal antibody comprises (i) a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and (ii) a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein:
- (a) CDRH1 CDRH2, and CDRH3 comprise the sequence of SEQ ID NOs:
- 165, 179, and 189, respectively, and CDRL1, CDRL2, and CDRL3 comprise the sequence of SEQ ID NOs:
- 140, 151, and 157, respectively;
- (b) CDRH1, CDRH2, and CDRH3 comprise the sequence of SEQ ID NOs:
- 165, 179, and 189, respectively, and CDRL1, CDRL2, and CDRL3 comprise the sequence of SEQ ID NOs;
- 139, 151, and 157, respectively;
- (c) CDRH1, CDRH2, and CDRH3 comprise the sequence of SEC) ID NOs:
- 167, 180, and 188, respectively, and CDRL1, CDRL2, and CDRL3 comprise the sequence of SEQ ID NOs:
- 139, 151, and 157, respectively;
- or
- (d) CDRH1, CDRH2, and CDRH3 comprise the sequence of SEQ ID NOs:
- 170, 183, and 185, respectively, and CDRL1, CDRL2, and CDRL3 comprise the sequence of SEQ ID NOs:
- 148, 155, and 162, respectively.
Dependencies are inferred from the claim text.